Lorenzo Cosmi1, Francesco Liotta1, Laura Maggi1, Francesco Annunziato2. 1. Department of Experimental and Clinical Medicine and DENOTHE Center, University of Florence, 50134, Florence, Italy. 2. Department of Experimental and Clinical Medicine and DENOTHE Center, University of Florence, 50134, Florence, Italy. francesco.annunziato@unifi.it.
Abstract
PURPOSE OF REVIEW: The adaptive immune response orchestrated by type 2 T helper (Th2) lymphocytes, strictly cooperates with the innate response of group 2 innate lymphoid cells (ILC2), in the protection from helminths infection, as well as in the pathogenesis of allergic disease. The aim of this review is to explore the pathogenic role of ILC2 in different type 2-mediated disorders. RECENT FINDINGS: Recent studies have shown that epithelial cell-derived cytokines and their responding cells, ILC2, play a pathogenic role in bronchial asthma, chronic rhinosinusitis, and atopic dermatitis. The growing evidences of the contribution of ILC2 in the induction and maintenance of allergic inflammation in such disease suggest the possibility to target them in therapy. Biological therapies blocking ILC2 activation or neutralizing their effector cytokines are currently under evaluation to be used in patients with type 2-dominated diseases.
PURPOSE OF REVIEW: The adaptive immune response orchestrated by type 2 T helper (Th2) lymphocytes, strictly cooperates with the innate response of group 2 innate lymphoid cells (ILC2), in the protection from helminths infection, as well as in the pathogenesis of allergic disease. The aim of this review is to explore the pathogenic role of ILC2 in different type 2-mediated disorders. RECENT FINDINGS: Recent studies have shown that epithelial cell-derived cytokines and their responding cells, ILC2, play a pathogenic role in bronchial asthma, chronic rhinosinusitis, and atopic dermatitis. The growing evidences of the contribution of ILC2 in the induction and maintenance of allergic inflammation in such disease suggest the possibility to target them in therapy. Biological therapies blocking ILC2 activation or neutralizing their effector cytokines are currently under evaluation to be used in patients with type 2-dominated diseases.
Authors: Alissa A Chackerian; Elizabeth R Oldham; Erin E Murphy; Jochen Schmitz; Stefan Pflanz; Robert A Kastelein Journal: J Immunol Date: 2007-08-15 Impact factor: 5.422
Authors: Ruchong Chen; Steven G Smith; Brittany Salter; Amani El-Gammal; John Paul Oliveria; Caitlin Obminski; Rick Watson; Paul M O'Byrne; Gail M Gauvreau; Roma Sehmi Journal: Am J Respir Crit Care Med Date: 2017-09-15 Impact factor: 21.405
Authors: Gail M Gauvreau; Paul M O'Byrne; Louis-Philippe Boulet; Ying Wang; Donald Cockcroft; Jeannette Bigler; J Mark FitzGerald; Michael Boedigheimer; Beth E Davis; Clapton Dias; Kevin S Gorski; Lynn Smith; Edgar Bautista; Michael R Comeau; Richard Leigh; Jane R Parnes Journal: N Engl J Med Date: 2014-05-20 Impact factor: 91.245
Authors: Matthew J Gold; Frann Antignano; Timotheus Y F Halim; Jeremy A Hirota; Marie-Renee Blanchet; Colby Zaph; Fumio Takei; Kelly M McNagny Journal: J Allergy Clin Immunol Date: 2014-04 Impact factor: 10.793
Authors: Andrea Vianello; Marco Caminati; Mariangiola Crivellaro; Rafi El Mazloum; Rossella Snenghi; Michele Schiappoli; Annarita Dama; Andrea Rossi; Giuliana Festi; Maria Rita Marchi; Chiara Bovo; Giorgio Walter Canonica; Gianenrico Senna Journal: World Allergy Organ J Date: 2016-12-14 Impact factor: 4.084
Authors: Christopher J Oliphant; You Yi Hwang; Jennifer A Walker; Maryam Salimi; See Heng Wong; James M Brewer; Alexandros Englezakis; Jillian L Barlow; Emily Hams; Seth T Scanlon; Graham S Ogg; Padraic G Fallon; Andrew N J McKenzie Journal: Immunity Date: 2014-07-31 Impact factor: 31.745
Authors: Cindy Barnig; Tjitske Bezema; Philip C Calder; Anne Charloux; Nelly Frossard; Johan Garssen; Oliver Haworth; Ksenia Dilevskaya; Francesca Levi-Schaffer; Evelyne Lonsdorfer; Marca Wauben; Aletta D Kraneveld; Anje A Te Velde Journal: Front Immunol Date: 2019-07-23 Impact factor: 7.561